Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia

Pedersen, Anya; Diedrich, M.; Kaestner, Florian; Koelkebeck, Katja; Ohrmann, Patricia; Ponath, Gerald; Kipp, Frank; Abel, Simone; Siegmund, Ansgar; Suslow, Thomas; Eiff, Christof von; Arolt, Volker; Rothermundt, Matthias

doi:10.1016/j.pnpbp.2008.07.017

Cited by 45 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, elevated S100B levels have been shown to be associated with poor cognitive function in schizophrenia patients [19]. By directly linking the above alleles to spatial disability in schizophrenia patients, the present study helped to complete the picture of the S100B gene and schizophrenia.…”

Section: Discussionmentioning

confidence: 75%

“…Because schizophrenia patients are reported to show elevated levels of S100B in their peripheral blood [13,19,23,24,28], cerebral spinal fluid [22], and cortical brain tissue [27] (see [24] for a comprehensive meta-analysis), the S100B gene has been considered as a candidate gene in the etiology of schizophrenia. More importantly for this study, Liu and colleagues [14], using 384 schizophrenia patients and 401 controls of Han Chinese origin, found that schizophrenia was significantly associated with haplotypes composed of rs1051169 and rs9722 (two SNPs in the S100B gene) and marginally associated with rs1051169 alone.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia

Zhai

Zhang

Cheng

et al. 2011

Behavioural Brain Research

View full text Add to dashboard Cite

a b s t r a c tRs9722 and rs1051169 have been reported as affecting the levels of S100B in the serum or the brain, and haplotypes containing these two SNPs have been associated with schizophrenia. The current study investigated the role of the S100B gene in an endophenotype of schizophrenia-spatial disability. 304 schizophrenia patients and 196 healthy controls were given a block design task and a mental rotation task. Results showed that the two aforementioned SNPs and related haplotypes were associated with the spatial disability of schizophrenia patients. Specifically, risk factors for the elevated S100B levels, including the A allele of rs9722, the G allele of rs1051169, and the AG haplotype, were associated with a poorer performance on both tests of spatial ability, especially the mental rotation task. These results implicate a role for S100B gene polymorphisms in the cognitive functions of schizophrenia patients and encourage further investigation into spatial disability as an endophenotype of schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia

Zhai

Zhang

Cheng

et al. 2011

Behavioural Brain Research

View full text Add to dashboard Cite

show abstract

“…In addition, patients with deficit syndrome [67] present higher S100B serum [48] and elevated serum S100B levels have linked to memory impairment [68].…”

Section: Discussionmentioning

confidence: 99%

Systematic Review and Meta-Analysis of Circulating S100B Blood Levels in Schizophrenia

et al. 2014

View full text Add to dashboard Cite

S100B is a calcium-binding protein secreted in central nervous system from astrocytes and other glia cells. High blood S100B levels have been linked to brain damage and psychiatric disorders. S100B levels have been reported to be higher in schizophrenics than healthy controls. To quantify the relationship between S100B blood levels and schizophrenia a systematic literature review of case-control studies published on this topic within July 3rd 2014 was carried out using three bibliographic databases: Medline, Scopus and Web of Science. Studies reporting mean and standard deviation of S100B blood levels both in cases and controls were included in the meta-analysis. The meta-Mean Ratio (mMR) of S100B blood levels in cases compared to controls was used as a measure of effect along with its 95% Confidence Intervals (CI). 20 studies were included totaling for 994 cases and 785 controls. Schizophrenia patients showed 76% higher S100B blood levels than controls with mMR = 1.76 95% CI: 1.44–2.15. No difference could be found between drug-free patients with mMR = 1.84 95%CI: 1.24–2.74 and patients on antipsychotic medication with mMR = 1.75 95% CI: 1.41–2.16). Similarly, ethnicity and stage of disease didn't affect results. Although S100B could be regarded as a possible biomarker of schizophrenia, limitations should be accounted when interpreting results, especially because of the high heterogeneity that remained >70%, even after carrying out subgroups analyses. These results point out that approaches based on traditional categorical diagnoses may be too restrictive and new approaches based on the characterization of new complex phenotypes should be considered.

show abstract

“…Thus, PBR binding might also arise from astrocytes and other non-microglial elements. Schizophrenia patients with high S100B serum concentration, considered to indicate astrocyte activation, were reported to have cognitive dysfunction compared with patients with low S100B serum concentration (Pedersen et al 2008). DAA1106 binding in patients with schizophrenia might also be related to the change in PBR on astrocytes.…”

Section: Discussionmentioning

confidence: 99%

Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106

Takano¹,

Arakawa²,

Ito³

et al. 2010

Int. J. Neuropsychopharm.

169

125

View full text Add to dashboard Cite

Inflammatory/immunological process and glial contribution are suggested in the pathophysiology of schizophrenia. We investigated peripheral benzodiazepine receptors in brains of patients with chronic schizophrenia, which were reported to be located on mitochondria of glial cells, using [11 C]DAA1106 with positron emission tomography. Fourteen patients and 14 age-and sex-matched normal controls participated in this study. PET data were analysed by two-tissue compartment model with metabolite-corrected plasma input. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale. There was no significant difference between [

show abstract

Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia

Cited by 45 publications

References 30 publications

Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia

Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia

Systematic Review and Meta-Analysis of Circulating S100B Blood Levels in Schizophrenia

Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106

Contact Info

Product

Resources

About